CHIUN HSUChang, Yi-FangYi-FangChangYen, Chia-JuiChia-JuiYenXu, Yu-WeiYu-WeiXuDong, MinMinDongTong, You-ZhiYou-ZhiTong2024-01-092024-01-092023-10-201741-7015https://scholars.lib.ntu.edu.tw/handle/123456789/638304GT90001 (also known as PF-03446962) is an anti-ALK-1 monoclonal antibody and has shown activity in hepatocellular carcinoma (HCC). This phase 1b/2 study was designed to determine the recommended phase 2 dose (RP2D) of GT90001 plus nivolumab, and assess the safety and anti-tumor activity in patients with advanced HCC.enAnti-angiogenic therapy; GT90001; Hepatocellular carcinoma; Immunotherapy; Nivolumab; PF-03446962[SDGs]SDG3Combination of GT90001 and nivolumab in patients with advanced hepatocellular carcinoma: a multicenter, single-arm, phase 1b/2 studyjournal article10.1186/s12916-023-03098-w378581842-s2.0-85174540357https://api.elsevier.com/content/abstract/scopus_id/85174540357